ITOS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

559.91M

Low

Amount

EV/EBITDA(TTM)

Total Shares

-66.75M

EV/OCF(TTM)

P/S(TTM)

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its EOS-984, a potentially first-in-class small molecule, focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1, a dominant transporter of extracellular adenosine, expressed on intratumoral T cells, which allows adenosine entry into the cell, disturbing T cell metabolism, expansion, effector function, and survival. It is also developing EOS-215, a potential best-in-class monoclonal antibody which antagonizes the triggering receptor expressed on myeloid cells 2.

Events Timeline

(ET)

2025-09-02

08:36:03

Vor Bio Names Osovsky as General Counsel

2025-07-21 (ET)

2025-07-21

08:43:46

Vor Bio appoints Cumbo, Detheux to board of directors

2025-07-21

07:32:50

iTeos to be acquired by Concentra for $10.047 per share in cash plus CVR

2025-05-28 (ET)

2025-05-28

08:32:25

iTeos Therapeutics announces intention to wind down operations

News

8.5

2025-09-05Globenewswire

$HAREHOLDER NOTICE: M&A Class Action Firm Ongoing Investigation into the Merger of MTWO, ITOS, DYNX, and PHLT

7.0

2025-08-20PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and KLG on Behalf of Shareholders

7.0

2025-08-19Globenewswire

Investor Alert from Former Louisiana Attorney General: Kahn Swick & Foti, LLC Examines Price and Process in iTeos Therapeutics, Inc. Sale - ITOS

4.0

2025-08-07Benzinga

Wells Fargo Maintains Equal-Weight on ITeos Therapeutics, Lowers Price Target to $11

7.0

2025-08-05PRnewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, CORZ, ITOS, VBTX on Behalf of Shareholders

7.0

2025-07-30Globenewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, VBTX, TTNP on Behalf of Shareholders July 31, 2025

4 Analyst Rating

Wall Street analysts forecast ITOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITOS is 10.26 USD with a low forecast of 10.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

4 Hold

0 Sell

Hold

Current: 0.000

Low

10.00

Averages

10.26

High

11.00

Current: 0.000

Low

10.00

Averages

10.26

High

11.00

Piper Sandler

Edward Tenthoff

Overweight -> Neutral

downgrade

$12

Al Analysis

2025-07-21

Reason

Piper Sandler

Edward Tenthoff

Price Target

$12

Al Analysis

2025-07-21

downgrade

Overweight -> Neutral

Reason

Piper Sandler analyst Edward Tenthoff downgraded iTeos Therapeutics to Neutral from Overweight with a price target of $10.05, down from $12, after the company entered into am merger agreement whereby Concentra Biosciences will acquire iTeos for $10.047 in cash per share.

Wedbush

Outperform -> Neutral

downgrade

2025-05-28

Reason

Wedbush

Price Target

2025-05-28

downgrade

Outperform -> Neutral

Reason

Wedbush downgraded iTeos Therapeutics to Neutral from Outperform.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ITOS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Iteos Therapeutics Inc (ITOS.O) is -1.73, compared to its 5-year average forward P/E of -67.97. For a more detailed relative valuation and DCF analysis to assess Iteos Therapeutics Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-67.97

Current PE

-1.73

Overvalued PE

211.65

Undervalued PE

-347.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.89

Current EV/EBITDA

1.20

Overvalued EV/EBITDA

3.69

Undervalued EV/EBITDA

-1.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

19.58

Current PS

26.76

Overvalued PS

60.01

Undervalued PS

-20.85

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Iteos Therapeutics Inc (ITOS) stock price today?

The current price of ITOS is 0 USD — it has increased 0 % in the last trading day.

What is Iteos Therapeutics Inc (ITOS)'s business?

What is the price predicton of ITOS Stock?

Wall Street analysts forecast ITOS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ITOS is10.26 USD with a low forecast of 10.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Iteos Therapeutics Inc (ITOS)'s revenue for the last quarter?

Iteos Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

What is Iteos Therapeutics Inc (ITOS)'s earnings per share (EPS) for the last quarter?

Iteos Therapeutics Inc. EPS for the last quarter amounts to -1.81 USD, increased 905.56 % YoY.

How many employees does Iteos Therapeutics Inc (ITOS). have?

Iteos Therapeutics Inc (ITOS) has 173 emplpoyees as of January 17 2026.

What is Iteos Therapeutics Inc (ITOS) market cap?

Today ITOS has the market capitalization of 559.91M USD.

ITOS Overview

ITOS Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

People Also Watch

Frequently Asked Questions

What is Iteos Therapeutics Inc (ITOS) stock price today?

What is Iteos Therapeutics Inc (ITOS)'s business?

What is the price predicton of ITOS Stock?

What is Iteos Therapeutics Inc (ITOS)'s revenue for the last quarter?

What is Iteos Therapeutics Inc (ITOS)'s earnings per share (EPS) for the last quarter?

How many employees does Iteos Therapeutics Inc (ITOS). have?

What is Iteos Therapeutics Inc (ITOS) market cap?